Pancreatic cancer from bench to bedside: molecular pathways and treatment options

Area of Science:

• Oncology
• Gastroenterology
• Molecular Biology

Background:

• Pancreatic cancer treatment has seen limited progress over 40 years, with a persistent 5% five-year survival rate.
• Early diagnosis and surgical resection remain the most effective treatment strategies for pancreatic cancer.
• Recent decades have significantly advanced the understanding of pancreatic cancer biology, identifying novel therapeutic targets.

Purpose of the Study:

• To provide a comprehensive overview of pancreatic cancer, from diagnosis to future therapeutic strategies.
• To review current and emerging treatment options based on molecular pathway exploration.
• To highlight the challenges in translating biological discoveries into improved patient outcomes.

Main Methods:

• Literature review of pancreatic cancer research over the past four decades.
• Analysis of diagnostic criteria and prognostic factors.
• Exploration of molecular pathways implicated in pancreatic cancer development and progression.

Main Results:

• Surgery is the optimal treatment for early-stage pancreatic cancer.
• Novel therapeutic agents, including tyrosine kinase inhibitors and vaccines, represent emerging treatment perspectives.
• Significant challenges persist in translating fundamental research into tangible improvements in patient survival rates.

Conclusions:

• Continued research into pancreatic cancer biology is crucial for developing more effective treatments.
• Translating molecular insights into clinical practice is essential to improve patient outcomes and survival.
• A multi-faceted approach combining early diagnosis, surgery, and novel therapeutic strategies is necessary for advancing pancreatic cancer care.